Skip to main content

News

All the latest news and information on the main advances in research, institutional milestones, teaching and management. Find out what happens at the Vall d'Hebron Research Institute!

You can now register for the Master's Degree in Translational Biomedical Research, the Master's Degree in Clinical Trial Management and Coordination and, as a novelty, the Master's Degree in Health Innovation and Entrepreneurship.

The EXPOSIM project will investigate the impact of environmental stressors such as pollution, noise and aeroallergens on immune-mediated diseases.

In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.

The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.

The Association for the Information and Research of Familial Hypomagnesemia, once again, has shown its solidarity with a donation of €19,000.

VHIR collaborates in the development of nanoGLA, an innovative nanotechnology therapy to treat Fabry disease. It has demonstrated high efficacy in preclinical studies, highlighting its effectiveness in addressing neurological manifestations.

A key initiative that connects researchers with a network of more than 20 external mentors who are experts in various fields within the ecosystem.

Members of the RBDCOV project, which involves VHIR, gathered at the Palau Macaya to review progress and achievements made during the final phase of the project.

The grants, totalling almost three million euros, promote the training of the next generation of research professionals and support the development of new technologies.

Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.

Hypertension, a key risk factor for heart disease that contributes significantly to cardiovascular mortality and morbidity and damage to vital organs, was the focus of this multi-centre study.

This project is promoted by the Pasqual Maragall Foundation with the support of Barcelona City Council. It involves some of the city's main public hospitals and institutions specialising in research into Alzheimer's disease.

The Parc Taulí and Vall d’Hebron spin-off has raised €2.77 million in private and public funds, enabling it to complete the necessary clinical trials to obtain CE marking and bring this device to market.

Vall d'Hebron researchers have created a score based on multiple clinical variables and cardiac images, specific to women, to identify patients at risk of severe complications such as a heart attack or sudden death.

The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.

INDICATE will lay the foundations for the training and operation of an AI model implemented in intensive care units to support personalised medicine applications, data comparison between ICUs and preparedness for possible disasters.

The sessions were aimed at establishing new collaborations to advance the prevention and treatment of this type of tumour.

A 17,000 m2 space dedicated to research, innovation and teaching, which is open to the public.

The new findings were presented at the American Society of Nephrology's Kidney Week 2024 meeting in San Diego and simultaneously published in the prestigious journal Nature Medicine.

A new consortium of leading organizations embarks on a groundbreaking project to enhance patient triage and healthcare delivery.

Over time, wild boars have approached the city of Barcelona and surrounding areas. As carriers of the hepatitis E virus, they are linked to a study identifying them as a potential source of transmission of this disease.

During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.